Risk Factors or Predictors of Developing Ciprofloxacin, Trimethoprim/Sulfamethoxazole and Third Generation Cephalosporin Resistance in Escherichia coli Infections: A Systematic Review and Meta-Analysis
Abstract
The Centers for Disease Control and Prevention (CDC) estimates that by 2050, ten million people a year could be dying as a result of Anti-Microbial Resistance (AMR). An increase in resistance has been observed for trimethoprim/sulfamethoxazole followed by ciprofloxacin and third-generation cephalosporins in the management of Escherichia coli infections. To identify risk factors for ciprofloxacin (Cip-REC), trimethoprim/sulfamethoxazole (TMP/SMX-REC,) and third-generation cephalosporin (TGC-REC) resistance in Escherichia coli infection relative to controls patients. A systematic search of MEDLINE/PubMed and Embase databases identified case-control, cohort, and cross-sectional studies on risk factors for Cip-REC, TMP/SMX-REC, and TGC-REC-infected patients. A random-effects model was used to pool odds ratios (ORs) of developing resistant E. coli infection. This study was registered with PROSPERO (CRD42022297043). A total of 23 studies were included (9891 participants). Overall, 22, 8, and 11 risk factors were identified for developing Cip-REC, TMP/SMX-REC, and TGC-REC infections respectively. The prior antibiotic use [OR=3.19] reported high pooled ORs for Cip-REC infection. TMP/SMX-REC infection was associated with genitourinary abnormalities [OR=2.91]. Further analysis unveiled potential factors for TGC-REC infection; prior history of admission [OR=3.14] and hemodialysis [OR=2.20]. Prior antibiotic usage, genitourinary disorders, and admission history increase the risk of Cip-REC, TMP/SMX-REC, and TGC-REC infections. Modifiable risk factors may help prevent resistant E. coli infection.
References
2. Torres AG, Arenas-Hernández MM, Martínez-Laguna Y. Overview of Escherichia coli. Pathog Escherichia Coli Lat Am 2010; 1–7.
3. Skogberg K, Lyytikäinen O, Ollgren J, et al. Population-based burden of bloodstream infections in Finland. Clin Microbiol Infect 2012; 18: E170–E176.
4. Bonten M, Johnson JR, van den Biggelaar AH, et al. Epidemiology of Escherichia coli bacteremia: a systematic literature review. Clin Infect Dis 2021; 72:1211–1219.
5. Kaye KS, Gupta V, Mulgirigama A, et al. Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011 to 2019: rising ESBL strains and impact on patient management. Clin Infect Dis 2021; 73:1992–1999.
6. MacKinnon MC, McEwen SA, Pearl DL, et al. Mortality in Escherichia coli bloodstream infections: a multinational population-based cohort study. BMC Infect Dis 2021; 21:1–10.
7. Walker E, Lyman A, Gupta K, et al. Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens. Clin Infect Dis 2016; 63:960–965.
8. Koulenti D, Song A, Ellingboe A, et al. Infections by multidrug-resistant Gram-negative Bacteria: What’s new in our arsenal and what’s in the pipeline? Int J Antimicrob Agents 2019; 53:211–224.
9. Deshwal PR, Reddy NS, Fathima R, et al. Risk factors or predictors of developing antibiotic resistance in Escherichia. coli infections relative to control patients: A Systematic review and meta-analysis. PROSPERO 2022 CRD42022297043, https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022297043 (2022).
10. Beller EM, Glasziou PP, Altman DG, et al. PRISMA for abstracts: reporting systematic reviews in journal and conference abstracts. PLoS Med 2013; 10: e1001419.
11. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1–e34.
12. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151:264–269.
13. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Stat Med 2002; 21:1539–1558.
14. Lasserson TJ, Thomas J, Higgins JP. Starting a review. Cochrane Handb Syst Rev Interv 2019; 1–12.
15. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
16. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54:1046–1055.
17. Collaboration C. Review Manager (RevMan) [Computer Program] Version 5.2. 3, The Nordic Cochrane Centre, Copenhagen, 2012. Health Psychol Rev; 17.
18. Pierce CA. Software Review: Borenstein, M., Hedges, LV, Higgins, JPT, & Rothstein, HR (2006). Comprehensive Meta-Analysis (Version 2.2. 027)[Computer software]. Englewood, NJ: Biostat. Organ Res Methods 2008; 11:188–191.
19. Cheong H-J, Yoo C-W, Sohn J-W, et al. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 2001; 33:48–53.
20. Eom J-S, Hwang B-Y, Sohn J-W, et al. Clinical and molecular epidemiology of quinolone-resistant Escherichia coli isolated from urinary tract infection. Microb Drug Resist 2002; 8:227–234.
21. Jadoon RJ, Khan SA. E. coli resistance to ciprofloxacin and common associated factors. J Coll Physicians Surg Pak 2015; 25:824–828.
22. Garau J, Xercavins M, Rodríguez-Carballeira M, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999; 43:2736–2741.
23. McDonald LC, Chen F-J, Lo H-J, et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother 2001; 45:3084–3091.
24. Park K-H, Oh WS, Kim ES, et al. Factors associated with ciprofloxacin-and cefotaxime-resistant Escherichia coli in women with acute pyelonephritis in the emergency department. Int J Infect Dis 2014; 23:8–13.
25. Kratochwill L, Powers M, McGraw MA, et al. Factors associated with ciprofloxacin-resistant Escherichia coli urinary tract infections in discharged ED patients. Am J Emerg Med 2015; 33:1473–1476.
26. Ahmed SS, Shariq A, Alsalloom AA, et al. Uropathogens and their antimicrobial resistance patterns: Relationship with urinary tract infections. Int J Health Sci 2019; 13:48.
27. Fulgenzio C, Massari M, Traversa G, et al. Impact of prior antibiotic use in primary care on Escherichia coli resistance to third generation cephalosporins: a case-control study. Antibiotics 2021; 10:451.
28. Smithson A, Chico C, Ramos J, et al. Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection. Eur J Clin Microbiol Infect Dis 2012; 31:423–430.
29. Gangcuangco LM, Alejandria M, Henson KE, et al. Prevalence and risk factors for trimethoprim–sulfamethoxazole-resistant Escherichia coli among women with acute uncomplicated urinary tract infection in a developing country. Int J Infect Dis 2015; 34:55–60.
30. Lin W-P, Huang Y-S, Wang J-T, et al. Prevalence of and risk factor for community-onset third-generation cephalosporin-resistant Escherichia coli bacteremia at a medical center in Taiwan. BMC Infect Dis 2019; 19:1–11.
31. Pena C, Albareda JM, Pallares R, et al. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995; 39:520–524.
32. Lee Y, Lee D-G, Lee SH, et al. Risk factor analysis of ciprofloxacin-resistant and extended spectrum beta-lactamases pathogen-induced acute bacterial prostatitis in Korea. J Korean Med Sci 2016; 31:1808–1813.
33. Ena J, Amador C, Martinez C, et al. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol 1995; 153:117–120.
34. Sotto A, De Boever CM, Fabbro-Peray P, et al. Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study. J Clin Microbiol 2001; 39:438–444.
35. Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004; 38:1148–1152.
36. Mulder M, Kiefte-de Jong JC, Goessens WH, et al. Risk factors for resistance to ciprofloxacin in community-acquired urinary tract infections due to Escherichia coli in an elderly population. J Antimicrob Chemother 2016; 72:281–289.
37. Allen UD, MacDonald N, Fuite L, et al. Risk factors for resistance to" first-line" antimicrobials among urinary tract isolates of Escherichia coli in children. Cmaj 1999; 160:1436–1440.
38. Nicoletti J, Kuster S, Sulser T, et al. Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland. Swiss Med Wkly 2010; w13059.
39. Lee S, Han SW, Kim KW, et al. Third-generation cephalosporin resistance of community-onset Escherichia coli and Klebsiella pneumoniae bacteremia in a secondary hospital. Korean J Intern Med 2014; 29:49.
40. Courpon-Claudinon A, Lefort A, Panhard X, et al. Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features. Clin Microbiol Infect 2011; 17:557–565.
41. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005; 41: S120–S126.
42. Urinary tract infection (recurrent): antimicrobial prescribing. NICE guideline, https://www.nice.org.uk/guidance/ng112/documents/draft-guideline#:~:text=Recurrent%20UTI%20in%20adults%20is,on%20urological%20infections%20%5B2017%5D). (2018).
43. Nelson CP, Hoberman A, Shaikh N, et al. Antimicrobial resistance and urinary tract infection recurrence. Pediatrics; 137.
44. Antimicrobial resistance stewardship-report. Centers for Disease Control and Prevention (CDC)., https://www.cdc.gov/antibiotic-use/stewardship-report/pdf/stewardship-report-2018-508.pdf (2018).
45. Costelloe C, Metcalfe C, Lovering A, et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. Bmj; 340.
46. Antibiotic resistance. Centers for Disease Control and Prevention (CDC). 2021. https://www.cdc.gov/drugresistance/about/how-resistance happens.html#:~:text=Antibiotic%20resistance%20is%20accelerated%20when,resistant%20germs%20survive%20and%20multiply. (2021).
47. Katouli M. Population structure of gut Escherichia coli and its role in development of extra-intestinal infections. Iran J Microbiol 2010; 2:59.
48. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab 2012; 16: S27.
49. Reis ACC, Santos SR da S, Souza SC de, et al. Ciprofloxacin resistance pattern among bacteria isolated from patients with community-acquired urinary tract infection. Rev Inst Med Trop São Paulo; 58.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.